AOD-9604 International Purchase Legalities: What You Need to Know in 2026

What Is AOD-9604 and Why Does Its Legal Status Get Complicated?

AOD-9604 is a synthetic 16-amino-acid C-terminal fragment of human growth hormone (hGH), spanning residues 176 to 191. Researchers originally isolated this fragment because it appeared to retain the fat-metabolizing properties of full hGH without measurable effects on insulin-like growth factor 1 (IGF-1) or glucose metabolism. That pharmacological profile attracted interest for obesity and metabolic applications throughout the 1990s and early 2000s.

The Drug Development History That Shapes Today's Legal Field

Metabolic Pharmaceuticals Ltd. Conducted a Phase IIb randomized controlled trial (NCT identifier ACTRN12605000065617) enrolling 300 obese adults. Participants received oral AOD-9604 at doses of 1 mg or 9 mg once daily for 12 weeks. Neither dose produced statistically significant weight loss versus placebo at the primary endpoint, and the program was discontinued before Phase III. Because AOD-9604 never completed an FDA new drug application (NDA), it has no approved indication in the United States and therefore cannot be marketed as a finished pharmaceutical product. [1]

Why Compounders Can Still Legally Prepare It

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare individualized, prescription-based formulations that are not commercially available as FDA-approved products. [2] AOD-9604 fits that category. A prescribing physician must issue a patient-specific prescription, and the compounding pharmacy must comply with U.S. Pharmacopeia (USP) standards for sterile compounding (USP <797>). The FDA's 2023 guidance on difficult-to-compound sterile preparations applies to injectable peptides, including sub-Q formulations of AOD-9604. [3]

U.S. Regulatory Framework for AOD-9604

The FDA does not list AOD-9604 on the Demonstrably Difficult to Compound (DDC) list or on the bulk drug substances list under 503B outsourcing facilities as of January 2026. That matters because 503B outsourcing facilities, which produce larger, non-patient-specific batches, are subject to cGMP requirements and stricter oversight than 503A pharmacies. [4]

503A vs. 503B: Which Applies?

A 503A pharmacy can compound AOD-9604 for an individual patient upon receipt of a valid prescription. A 503B outsourcing facility cannot legally produce AOD-9604 in bulk unless the peptide appears on the FDA's bulk drug substances list for 503B use, which it does not. Patients ordering through telehealth platforms should confirm their supplier is a 503A-licensed pharmacy in the state where they reside or where the prescription is written. [5]

DEA Scheduling

AOD-9604 is not scheduled under the Controlled Substances Act. [6] Possession without a prescription is therefore not a federal criminal offense in the same sense that a Schedule II or III substance would be. It remains, however, a misdemeanor offense under 21 U.S.C. § 331 to receive a prescription drug without a valid prescription.

FDA Import Enforcement: The Personal-Use Exception Is Not a Right

The FDA's Regulatory Procedures Manual Chapter 9-2 describes a personal-use import policy under which agents may exercise enforcement discretion for a 90-day personal supply of unapproved drugs, provided the drug does not present an unreasonable risk and the individual is not importing for commercial redistribution. [7] This is discretionary, not a statutory right. CBP and FDA do seize shipments that arrive without proper documentation, and the agency has increased scrutiny of peptide imports since 2022 following warning letters to multiple overseas suppliers. [8]

Practically: ordering AOD-9604 from a foreign website ships the product through customs without FDA oversight of sterility, potency, or identity testing. Even if seizure does not occur, the patient has no assurance the product contains what the label claims.

International Legal Status by Jurisdiction

Australia

Australia has the most developed regulatory history with AOD-9604. Metabolic Pharmaceuticals, an Australian company, developed the peptide, and the Therapeutic Goods Administration (TGA) evaluated it extensively. As of 2026, AOD-9604 is listed under Schedule 4 (Prescription Only Medicine) of the Poisons Standard when compounded for human use. [9] Personal importation without a valid Australian prescription and TGA authorization is prohibited under the Therapeutic Goods Act 1989. Travelers carrying AOD-9604 into Australia without documentation risk confiscation and a civil penalty. The TGA's Personal Importation Scheme allows up to a 3-month supply of a Schedule 4 medicine for personal therapeutic use, provided the traveler has documentation from an Australian-registered medical practitioner. [10]

Canada

Health Canada classifies AOD-9604 as a new drug under Section 2 of the Food and Drugs Act. No manufacturer holds a Notice of Compliance (NOC) for AOD-9604 in Canada. [11] Canadian compounding pharmacies can prepare it under the personal-use exemption in the Food and Drug Regulations (C.01.040.2), but only upon receipt of a valid Canadian prescription. Importing personal supplies from the United States or overseas is technically non-compliant; Health Canada border officers have discretion but may seize shipments. The Canadian Compounding Pharmacists Association advises patients to use domestically licensed compounders rather than cross-border sourcing. [12]

United Kingdom

The Medicines and Healthcare products Regulatory Agency (MHRA) has not issued a marketing authorization for AOD-9604. Under the Human Medicines Regulations 2012, it may be supplied in the UK only under a Specials license or through a registered pharmacy on a named-patient basis with a valid prescription. [13] Importing AOD-9604 from overseas vendors without MHRA authorization is illegal. The MHRA issued a safety alert in 2023 warning about unregulated peptides sold online, explicitly citing HGH fragments. [14]

European Union

No EU marketing authorization exists for AOD-9604. Each member state applies its own compounding rules. Germany, France, and the Netherlands allow magistral (individualized) compounding with a physician prescription but prohibit import of compounded injectables from non-EU manufacturers. Italy's AIFA and Spain's AEMPS have similarly restricted access to compounded peptides that lack EU-GMP manufacturing documentation.

Jurisdictions Where AOD-9604 Exists in a Gray Zone

Several Southeast Asian nations, Eastern European countries, and certain Latin American markets have limited or no specific regulation covering synthetic peptide fragments. Research-grade AOD-9604 is marketed openly in these regions. "Research chemical" labeling does not confer any legal protection for human use, and products sold under this label are not manufactured to pharmaceutical GMP standards. The World Anti-Doping Agency (WADA) prohibits AOD-9604 under the S2 category of its Prohibited List, and athletes in any jurisdiction can face competition sanctions regardless of local legality. [15]

How to Get AOD-9604 Through Legitimate U.S. Telehealth Channels

The lowest-risk and most cost-efficient pathway for a U.S. Resident is a domestic telehealth consultation followed by prescription fulfillment through a licensed 503A compounding pharmacy. The process typically involves four steps.

Step 1: Telehealth Clinical Evaluation

A licensed provider reviews medical history, body composition data, and metabolic labs. AOD-9604 is most commonly prescribed in the context of weight management or body composition goals, and providers often order a baseline metabolic panel, fasting insulin, and an HbA1c before writing. Given that the peptide's mechanism involves lipolytic signaling through beta-3 adrenergic and other pathways, providers may also assess thyroid function, since subclinical hypothyroidism can blunt fat-loss responses to any agent. [16]

Step 2: Prescription Issuance and Pharmacy Selection

The prescribing provider sends the script to a PCAB-accredited (Pharmacy Compounding Accreditation Board) 503A pharmacy. PCAB accreditation is voluntary but signals adherence to USP <797> sterility and potency standards. Patients should confirm the pharmacy holds state licensure in their home state and that each batch undergoes third-party certificate of analysis (COA) testing for potency, sterility, endotoxin levels, and absence of microbial contamination. [17]

Step 3: Product Receipt and Storage

Licensed 503A compounders ship AOD-9604 refrigerated, typically at 2 to 8 degrees Celsius. Upon reconstitution (if lyophilized), the peptide should be stored at 2 to 8 degrees C and used within 28 days per standard compounding guidelines. [18] Shipping from an unregulated overseas supplier has no cold-chain guarantees, which degrades peptide integrity and reduces clinical effect even when the product nominally reaches the destination.

Step 4: Ongoing Monitoring

Responsible prescribers schedule a 6 to 8 week follow-up to assess response, adverse effects (most commonly transient injection-site reactions), and the need for dose adjustment. The typical starting dose used in U.S. Compounding programs is 250 to 500 mcg subcutaneously once daily, based on the dose ranges tested in Metabolic Pharmaceuticals' clinical program, although no FDA-approved dosing protocol exists. [19]

AOD-9604 Cost Reduction Strategies

Understanding the Price Drivers

Compounding costs for injectable peptides reflect pharmaceutical-grade raw material sourcing, USP <797> cleanroom overhead, third-party COA testing, and cold-chain shipping. Raw material purity certification to at least 99% by HPLC is a standard requirement for human-use compounding. [20] Websites offering AOD-9604 at dramatically lower prices than U.S. Compounders are almost certainly supplying research-grade material without pharmaceutical-grade testing.

Telehealth Subscription Programs

Several U.S. Telehealth platforms bundle monthly provider oversight, lab ordering, and pharmacy fulfillment into a subscription fee. For metabolic peptide programs, bundled pricing can reduce the effective per-vial cost compared to a la carte compounding by an estimated 20 to 35%, primarily because the subscription model creates volume purchasing arrangements between the platform and its pharmacy partners. Patients should verify the subscription explicitly includes a licensed compounding pharmacy, not a third-party fulfillment service acting as a middleman.

Formulary and Concentration Optimization

AOD-9604 is compounded at various concentrations, commonly 2 mg/mL, 5 mg/mL, and 10 mg/mL. A higher-concentration formulation means fewer vials per treatment cycle, reducing per-dose cost. Asking the prescriber to specify a 5 mg/mL or 10 mg/mL concentration rather than the default 2 mg/mL can meaningfully lower monthly expenditure without changing the clinical dose.

HSA and FSA Use for AOD-9604

This is an area where patients frequently receive incorrect information. Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) are governed by IRS Publication 502, which defines qualified medical expenses as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. [21] A compounded prescription drug dispensed by a licensed pharmacy to treat a diagnosed medical condition qualifies as a medical expense under Section 213(d) of the Internal Revenue Code. [22]

AOD-9604, when prescribed for a diagnosis coded under ICD-10-CM (for example, E66.09 for other obesity, or E78.5 for hyperlipidemia), and dispensed by a licensed 503A compounding pharmacy, meets the statutory definition of a qualified medical expense. The patient should obtain a Letter of Medical Necessity (LMN) from the prescribing provider. The LMN should specify the diagnosis, the medical rationale for the compounded drug, and the expected duration of therapy. Without an LMN, FSA/HSA card transactions for compounded drugs may be flagged for substantiation, and the account holder may be required to repay the amount as a non-qualified distribution.

IRS Notice 2019-45 expanded the list of preventive care treatments eligible for HDHP/HSA use to include certain chronic condition treatments even before the deductible is met, though this expansion targeted specific drug classes for defined conditions and does not automatically cover AOD-9604. [23] Patients should consult a tax professional before treating AOD-9604 costs as HSA/FSA-qualified if the diagnosis does not clearly map to a recognized ICD-10 code.

Safety and Quality Assurance Considerations

Regulatory status and legal access are only part of the picture. Product quality directly affects both safety and efficacy.

What Third-Party Testing Should Cover

A reputable 503A compounding pharmacy provides a COA for each batch that includes: identity confirmation by HPLC or mass spectrometry, potency (percentage of labeled claim, target 90 to 110%), sterility per USP <71>, endotoxin per USP <85>, and particulate matter per USP <788>. [24] Overseas research-grade suppliers rarely perform all five tests, and the few that publish COAs often use internal testing without third-party verification.

Adverse Effect Profile from Published Data

The Phase IIb trial conducted by Metabolic Pharmaceuticals reported that AOD-9604 at oral doses up to 9 mg/day over 12 weeks produced no clinically significant changes in fasting glucose, HbA1c, IGF-1, or standard safety labs compared to placebo. [1] Subcutaneous injection, the route used in compounding programs, has not been studied in a large randomized controlled trial at the doses currently prescribed. Injection-site reactions (erythema, mild induration) are the most frequently reported adverse events in clinical practice. No published evidence links AOD-9604 to carcinogenicity or cardiovascular risk at current compounding doses, though long-term data beyond 12 weeks of continuous use is absent from the peer-reviewed literature. [25]

Interaction With Anti-Doping Rules

Athletes subject to WADA, USADA, or sport-governing-body testing should be aware that AOD-9604 appears on the WADA 2026 Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). [15] A valid therapeutic use exemption (TUE) is theoretically available but extremely unlikely to be granted for a weight-management indication without an approved drug status. Any competitive athlete considering AOD-9604 should obtain formal TUE review before use.

Comparing U.S. Telehealth Access vs. International Gray-Market Sourcing

| Factor | U.S. 503A Telehealth | International Gray Market | |---|---|---| | Legal status | Fully compliant with prescription | Likely non-compliant with U.S. Import law | | Pharmaceutical-grade testing | Required (USP <797>, COA) | Rarely performed to pharma standards | | Cold-chain shipping | Standard | Typically absent | | Medical oversight | Licensed prescriber required | None | | HSA/FSA eligibility | Yes, with LMN | No (not a prescription from a licensed U.S. Pharmacy) | | Estimated cost per vial | $80, $200 (5 mg/mL) | $30, $80 (research grade) | | Seizure at customs | N/A (domestic shipment) | Possible; no recourse |

The apparent cost advantage of gray-market sourcing narrows significantly once the risks of product quality, import seizure, and loss of HSA/FSA eligibility are factored in.